Evaluation of BNT162b2 Covid-19 Vaccine in Children Younger than 5 Years of Age.
Flor M MuñozLawrence D SherCharu SabharwalAlejandra GurtmanXia XuNicholas KitchinStephen LockhartRobert RiesenbergJoanna M SexterHanna CzajkaGrant C PaulsenYvonne MaldonadoEmmanuel B WalterKawsar R TalaatJanet A EnglundUzma N SarwarCaitlin HansenMartha IwamotoChris WebberLuke CunliffeBenita UkkonenSilvina N MartínezBarbara A PahudIona MunjalJoseph B DomachowskeKena A SwansonHua MaKenneth KourySusan MatherClaire LuJing ZouXuping XiePei-Yong ShiDavid CooperÖzlem TüreciUğur ŞahinKathrin U JansenWilliam C Grubernull nullPublished in: The New England journal of medicine (2023)
A three-dose primary series of 3-μg BNT162b2 was safe, immunogenic, and efficacious in children 6 months to 4 years of age. (Funded by BioNTech and Pfizer; ClinicalTrials.gov number, NCT04816643.).
Keyphrases